Management Options in Locally Advanced Pancreatic Cancer
Management Options in Locally Advanced Pancreatic Cancer
复制标题
DOI：
10.1007/s11912-014-0388-y
复制
发表时间：
2014-06-01
影响因子：
4.7
通讯作者：
Herman, Joseph M.
中科院分区：
文献类型：
--
作者：
Mian, Omar Y.;Ram, Ashwin N.;Herman, Joseph M.
胰腺导管腺癌是一种高致死性癌症，在发病时很少能治愈。不幸的是，大多数患者被诊断患有转移性或局部晚期疾病，由于不完全切除的可能性很高，因此不适合手术。考虑到通常预后不良，转移失败的倾向大于局部失败的倾向，治疗选择是可变的，包括化疗、放疗、靶向治疗及其组合。本文综述了目前的证据，确定性管理的局部晚期胰腺癌，以及姑息治疗的作用。未来的发展方向，包括预测生物标志物和新的全身性药物的开发，也进行了讨论。
Pancreatic ductal adenocarcinoma is a highly lethal cancer that is rarely curable at the time of presentation. Unfortunately, most patients are diagnosed with either metastatic or locally advanced disease, which is not amenable to surgery owing to the high likelihood of incomplete resection. Given the generally poor prognosis with propensity for metastatic failure greater than that for local failure, treatment options are variable, and include chemotherapy, radiotherapy, targeted therapies, and combinations thereof. This review summarizes the current evidence for definitive management of locally advanced pancreatic adenocarcinoma, as well as the role of palliative therapies. Future directions, including the development of predictive biomarkers and novel systemic agents, are also discussed.